The Journal of Cardiac Failure is a premier peer-reviewed publication dedicated to advancing the understanding and management of heart failure and associated cardiovascular conditions. Published by Churchill Livingstone Inc Medical Publishers, this esteemed journal serves as a vital resource for researchers, clinicians, and healthcare professionals committed to improving patient outcomes in cardiology. With a notable impact factor and ranked in the Q1 category of Cardiology and Cardiovascular Medicine, the journal is recognized for its rigorous scholarly contributions, currently holding a position within the top 15% of its field according to Scopus rankings. The journal spans a comprehensive range of topics, from clinical practices to innovative research in heart failure, fostering knowledge dissemination and collaboration among experts. As it converges from 1994 to 2024, the Journal of Cardiac Failure remains dedicated to publishing high-quality research that shapes the future of cardiovascular medicine, ensuring accessible and impactful scientific dialogue.

The Egyptian Heart Journal, published by Springer, is a premier open-access journal dedicated to advancing the field of cardiology and cardiovascular medicine. As of 2023, it holds a Q3 classification within the category, showcasing its growing influence within the research community, and ranks 241 out of 387 in Scopus, reflecting a 37th percentile position. With an E-ISSN of 2090-911X, this journal has been open access since 2011, making it easily accessible to researchers, practitioners, and students alike. The journal aims to disseminate high-quality research articles, reviews, and case studies that contribute to the understanding and treatment of cardiovascular diseases. With its focus on innovative and practical solutions in cardiology, the Egyptian Heart Journal plays a critical role in shaping current and future cardiovascular research. Its global outreach and commitment to open access ensure that vital information is available to a wide audience, enhancing both scholarly discourse and clinical practice in the evolving landscape of cardiovascular medicine.

Kidney Diseases is an esteemed open-access journal published by KARGER that has been at the forefront of nephrology research since its inception in 2015. With an impressive Scopus ranking of #13 out of 81 in the field of Medicine Nephrology, placing it in the top 84th percentile, the journal has established itself as a vital resource for researchers, clinicians, and students interested in advancing knowledge on kidney health, disorders, and innovative treatment strategies. This journal aims to disseminate cutting-edge findings and clinical insights over a converged publication span from 2019 to 2024, fostering global collaboration and dialogue within the scientific community. With its commitment to open access, Kidney Diseases ensures that critical research is freely accessible, promoting wider dissemination of knowledge and the development of effective therapeutic interventions.

Journal of Clinical Hypertension, published by WILEY, is a leading open-access journal focused on advancing the understanding and treatment of hypertension and related cardiovascular conditions. With an ISSN of 1524-6175 and an E-ISSN of 1751-7176, the journal provides a vital platform for researchers, healthcare professionals, and students alike to disseminate high-quality, peer-reviewed research. Since transitioning to open access in 2021, it has increased its reach and accessibility, ensuring critical information is available to a broader audience. The journal holds an impressive position in the Scopus ranks, nestled within the Q2 quartile across key disciplines including Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, and Internal Medicine, indicating a strong impact on the scientific community. With articles converging from 2001 to 2024, it not only highlights contemporary developments but also contributes to the ongoing dialogue in the field. Researchers are encouraged to submit their findings on hypertension, treatment methodologies, and epidemiology to further enhance the collective knowledge in this crucial area of health.

BLOOD PRESSURE MONITORING is a distinguished academic journal published by Lippincott Williams & Wilkins, dedicated to advancing the study of blood pressure measurement and management across various medical disciplines. With an ISSN of 1359-5237 and an E-ISSN of 1473-5725, this journal has consistently contributed to the field since its inception in 1996, continuing to provide invaluable insights through 2024. Notably, the journal ranks in the Q2 quartile for Advanced and Specialized Nursing and Assessment and Diagnosis, illustrating its influence in these areas, while also making significant contributions to Cardiology, Internal Medicine, and broader Medical research. Although it does not currently offer open access, BLOOD PRESSURE MONITORING remains essential reading for researchers, healthcare professionals, and students, eager to stay at the forefront of blood pressure research and its critical implications in clinical practice. The journal's commitment to quality and rigor makes it a vital resource for anyone involved in the continuously evolving fields of cardiovascular health and patient monitoring.

The Journal of Asthma and Allergy, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing research in the fields of immunology, allergy, and pulmonary medicine. Since its inception in 2008, this journal has provided a vital platform for disseminating high-quality, peer-reviewed research that explores the complexities of asthma and allergy, allowing researchers, professionals, and students to access critical insights without subscription barriers. With an impressive impact factor reflected in its 2023 quartile rankings (Q2) in both Immunology and Allergy, as well as Pulmonary and Respiratory Medicine, the journal stands as a significant contributor to the scientific community, promoting innovative findings that support clinical practice and patient care. Based in New Zealand, the Journal of Asthma and Allergy continues to be at the forefront of research, from its dedication to publishing cutting-edge studies to fostering an inclusive academic discourse that spans the globe. Access to relevant articles is available online, ensuring that all stakeholders in these fields can stay informed and engaged.

Journal fur Hypertonie is a leading academic journal published by KRAUSE & PACHERNEGG GMBH, dedicated to the critical field of hypertension research. Since its inception in 1998, the journal has served as a vital platform for disseminating pioneering studies and advancements in the diagnosis, treatment, and management of hypertension. Although its Scopus coverage was discontinued in 2016, the journal continues to hold significance within the academic community, evidenced by its ranking of #98 out of 124 in Internal Medicine, placing it in the 21st percentile. This reflects its targeted impact and relevance in the evolving landscape of cardiovascular research. With no Open Access options, the journal remains a specialized resource indispensable for researchers, healthcare professionals, and students focused on enhancing their understanding and clinical practices related to hypertension. The journal's address is MOZARTGASSE 10, GABLITZ 3003, AUSTRIA.

Chronic Obstructive Pulmonary Diseases - Journal of the COPD Foundation, published by the esteemed COPD Foundation, serves as a vital platform for advancing research in the field of pulmonary and respiratory medicine. With an ISSN of 2372-952X, this journal emphasizes the exploration and dissemination of knowledge related to chronic obstructive pulmonary disease (COPD) while addressing broader topics in respiratory health. Recognized within the Q2 category of the 2023 *Scopus* rankings and positioned at the 47th percentile in its field, the journal showcases innovative studies, clinical insights, and evidence-based practices crucial for professionals, researchers, and students alike. Although operating as a traditional publication, it seeks to provide immediate access to groundbreaking research on the prevention and management of COPD, facilitating improved patient outcomes. As it continues to expand its influence since its convergence in 2018, this journal is dedicated to bridging gaps in pulmonary medicine, making it an indispensable resource for the global respiratory health community.

Clinical and Experimental Hypertension, published by Taylor & Francis Inc, is a crucial resource in the fields of internal medicine and physiology. With its inaugural publication dating back to 1978, this esteemed journal has successfully merged decades of research, providing a platform for the latest advancements in hypertension studies. Operating without an open access model, it is configured to serve a specialized audience of researchers, clinicians, and students who are dedicated to exploring innovative treatment modalities and understanding the complexities of hypertensive diseases. Ranked in the Q3 category in both Internal Medicine and Physiology, this journal accomplishes a commendable standing in the academic community, exemplified by its Scopus rankings which position it within the median percentile range in its field. By disseminating high-quality research and fostering scientific dialogue, Clinical and Experimental Hypertension plays a pivotal role in shaping contemporary understanding and clinical practices concerning hypertension management.

Pulmonary Circulation is a leading open-access journal published by Wiley, focused on advancing the field of pulmonary and respiratory medicine. Established in 2011, the journal has garnered a prestigious reputation, achieving a Q2 ranking in 2023 among its category and ranking #70 out of 155 in Scopus within the specialty of Medicine – Pulmonary and Respiratory Medicine, reflecting its growing influence and relevance in the scientific community. With its commitment to delivering high-quality, peer-reviewed research, Pulmonary Circulation serves as a vital resource for researchers, clinicians, and students seeking to explore innovative ideas and findings in lung health, pulmonary vascular diseases, and therapeutic approaches. The journal has been open access since 2017, ensuring that groundbreaking research is accessible to a wider audience, thus promoting collaboration and knowledge exchange in this dynamic field. Located in the heart of the United States at 111 River St, Hoboken, NJ 07030-5774, the journal is dedicated to fostering advancements in pulmonary health and addressing real-world challenges facing patients globally.